5
Ambalal Sarabhai Enterprises Ltd
AMBALALSA NSE
Ambalal Sarabhai Enterprises Ltd
HealthcareNSE: AMBALALSA BSE: 500009 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹245 Cr
Volatility
Moderate
P/E Ratio
21.65
EBITDA
₹26.90 Cr
Return on Equity
11.24%
Debt to Equity
0.18
Book Value
₹20.66
52W High
₹38.5
52W Low
₹30.3
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Ambalal Sarabhai Enterprises Ltd insights
40 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Company has delivered good profit growth of 43.9% CAGR over last 5 years
Weaknesses
6- Stock is trading at 4.04 times its book value
- Promoter holding is low: 31.4%
- Tax rate seems low
- Company has a low return on equity of 12.1% over last 3 years.
- Earnings include an other income of Rs.15.6 Cr.
- Working capital days have increased from 267 days to 1,379 days
Growth Rate
Revenue Growth
4.72% ↘
Net Income Growth
263.27% ↗
Cash Flow Change
176.05% ↗
ROE
219.32% ↗
ROCE
105.48% ↗
EBITDA Margin (Avg.)
32.09% ↘
Quarterly Results
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.37 | 1.7 | 0.8 | 0.33 | 0.99 | 1.14 | 0 | 1.17 | 1.73 | 1.64 | 0.79 | 0 | 1.52 |
| Expenses | 1.66 | 4.84 | 2.13 | 1.96 | 1.64 | 2.41 | 1.8 | 3.74 | 3.43 | 2.83 | 2.43 | 0.94 | 2.88 |
| Operating Profit | -1.29 | -3.14 | -1.33 | -1.63 | -0.65 | -1.27 | -1.8 | -2.57 | -1.7 | -1.19 | -1.64 | -0.94 | -1.36 |
| OPM % | -348.65% | -184.71% | -166.25% | -493.94% | -65.66% | -111.4% | — | -219.66% | -98.27% | -72.56% | -207.59% | — | -89.47% |
| Other Income | 2.6 | 1.18 | 1.96 | 1.33 | 3.41 | 1.88 | 6.37 | 10.81 | -3.21 | 8.17 | 1.36 | 2.89 | 3.16 |
| Interest | 0.05 | 0.03 | 0.04 | 0.06 | 0.07 | 0.09 | 0.09 | 0.1 | 0.05 | 0.07 | 0.08 | 0.09 | 0.17 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| PBT | 1.23 | -2.02 | 0.56 | -0.39 | 2.66 | 0.49 | 4.45 | 8.12 | -4.98 | 6.89 | -0.38 | 1.84 | 1.61 |
| Tax % | 8.94% | 0% | 0% | 69.23% | -76.32% | 6.12% | 3.15% | -3.82% | -0.4% | 0% | 0% | -0.54% | -64.6% |
| Net Profit | 1.12 | -2.02 | 0.56 | -0.65 | 4.7 | 0.46 | 4.31 | 8.43 | -4.96 | 6.88 | -0.38 | 1.84 | 2.65 |
| EPS in Rs | 0.15 | -0.26 | 0.07 | -0.08 | 0.61 | 0.06 | 0.56 | 1.1 | -0.65 | 0.9 | -0.05 | 0.24 | 0.35 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15 | 7 | 2 | 1 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 |
| Expenses | 27 | 29 | 14 | 22 | 9 | 8 | 12 | 6 | 9 | 9 | 11 | 9 |
| Operating Profit | -12 | -22 | -13 | -21 | -9 | -8 | -12 | -6 | -5 | -5 | -7 | -5 |
| OPM % | -79% | -310% | -858% | -2265% | — | — | — | -4292% | -139% | -126% | -181% | -130% |
| Other Income | 14 | 96 | -1 | 24 | 6 | 25 | 3 | 9 | 10 | 8 | 16 | 16 |
| Interest | 8 | 2 | 3 | 1 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 0 |
| Depreciation | 3 | 15 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -9 | 58 | -19 | 2 | -3 | 16 | -9 | 3 | 4 | 1 | 8 | 10 |
| Tax % | 0% | 21% | 10% | 166% | 13% | 2% | -1% | 14% | 5% | -217% | -2% | -10% |
| Net Profit | -9 | 46 | -21 | -1 | -4 | 16 | -9 | 3 | 4 | 3 | 8 | 11 |
| EPS in Rs | -1.19 | 5.96 | -2.68 | -0.19 | -0.51 | 2.03 | -1.23 | 0.39 | 0.54 | 0.34 | 1.08 | 1.43 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 |
| Reserves | -73 | -28 | -46 | -48 | -52 | -36 | -46 | -43 | -39 | -36 | -28 | -17 |
| Borrowings | 30 | 30 | 22 | 11 | 11 | 11 | 11 | 10 | 11 | 10 | 8 | 11 |
| Other Liabilities | 103 | 65 | 64 | 91 | 103 | 73 | 58 | 40 | 30 | 31 | 27 | 15 |
| Total Liabilities | 136 | 144 | 116 | 131 | 139 | 125 | 100 | 83 | 80 | 81 | 83 | 86 |
| Fixed Assets | 43 | 21 | 16 | 15 | 15 | 14 | 14 | 13 | 13 | 13 | 12 | 12 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 56 | 83 | 76 | 56 | 56 | 56 | 27 | 26 | 26 | 25 | 25 | 25 |
| Other Assets | 37 | 40 | 24 | 60 | 68 | 54 | 60 | 44 | 41 | 43 | 45 | 48 |
| Total Assets | 136 | 144 | 116 | 131 | 139 | 125 | 100 | 83 | 80 | 81 | 83 | 86 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -12 | -69 | -4 | -13 | -3 | -5 | -10 | -8 | 2 | -4 | -4 | 0 |
| Investing | 13 | 75 | 9 | 26 | 2 | 5 | 16 | 21 | 1 | 3 | 6 | -3 |
| Financing | -1 | -3 | -8 | -12 | 0 | 0 | 0 | -16 | -4 | 0 | -2 | 3 |
| Net Cash Flow | 0 | 3 | -3 | 1 | -1 | 0 | 5 | -3 | -2 | 0 | 0 | 0 |
| Free Cash Flow | 0 | 31 | -3 | 2 | -3 | -4 | 1 | 11 | 2 | -4 | 1 | 0 |
| CFO/OP | 71 | 304 | 27 | -24 | -11 | 51 | 85 | 128 | -45 | 65 | 47 | 61 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 37 | 2 | 0 | 0 | — | — | — | 421 | 30 | 37 | 37 | 39 |
| Inventory Days | 76 | 23 | 48 | 57 | — | — | — | 0 | 2 | 0 | 0 | 7 |
| Days Payable | 321 | 729 | 3,974 | 13,253 | — | — | — | — | 1,612 | — | — | 712 |
| Cash Conversion Cycle | -207 | -705 | -3,927 | -13,197 | — | — | — | 421 | -1,580 | 37 | 37 | -667 |
| Working Capital Days | -2,355 | -3,036 | -16,106 | -23,785 | — | — | — | -30,660 | -1,038 | -687 | 109 | 1,379 |
| ROCE % | -34% | -60% | -13% | -22% | -7% | 37% | -4% | 10% | 11% | 6% | 6% | 16% |
Documents
1
Intimation Regarding Change In Branch Address Of Registrar & Share Transfer Agent (MCS Share Transfer Agent Limited)
24 Apr - RTA MCS Share Transfer Agent’s branch shifts from Vadodara to Mumbai. 24 Apr - RTA MCS Share Transfer Agent’s branch shifts from Vadodara to Mumbai.
2
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
21 Apr - Company says it is not a Large Corporate for FY ended March 31, 2026. 21 Apr - Company says it is not a Large Corporate for FY ended March 31, 2026.
3
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
21 Apr - Annual disclosure for FY 2025-26 filed; no incremental borrowing or penalty applicable. 21 Apr - Annual disclosure for FY 2025-26 filed; no incremental borrowing or penalty applicable.
4
Intimation Regarding Change In Branch Address Of Registrar & Share Transfer Agent (MCS Share Transfer Agent Limited)
10h - RTA MCS Share Transfer Agent’s branch shifts from Vadodara to Mumbai. 10h - RTA MCS Share Transfer Agent’s branch shifts from Vadodara to Mumbai.
5
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
2d - Company says it is not a Large Corporate for FY ended March 31, 2026. 2d - Company says it is not a Large Corporate for FY ended March 31, 2026.
Frequently Asked Questions about Ambalal Sarabhai Enterprises Ltd
What does Ambalal Sarabhai Enterprises Ltd do?
Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics[1]
Where is Ambalal Sarabhai Enterprises Ltd (500009) listed?
Ambalal Sarabhai Enterprises Ltd is listed on the Indian stock exchanges. It is listed on NSE: AMBALALSA and BSE: 500009. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Ambalal Sarabhai Enterprises Ltd belong to?
Ambalal Sarabhai Enterprises Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Ambalal Sarabhai Enterprises Ltd?
Ambalal Sarabhai Enterprises Ltd has a market capitalisation of approximately ₹244.84 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Ambalal Sarabhai Enterprises Ltd?
The Price-to-Earnings (PE) ratio of Ambalal Sarabhai Enterprises Ltd is 21.65. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Ambalal Sarabhai Enterprises Ltd?
Over the past 52 weeks, Ambalal Sarabhai Enterprises Ltd has traded between a low of ₹30.3 and a high of ₹38.5. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Ambalal Sarabhai Enterprises Ltd?
Ambalal Sarabhai Enterprises Ltd has a Return on Equity (ROE) of 11.24%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Ambalal Sarabhai Enterprises Ltd on Tapetide?
On Tapetide, you can view Ambalal Sarabhai Enterprises Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics[1]
Website ase.life
Face Value ₹ 10